Immuneering to Highlight Atebimetinib Combination Potential at 2026 Symposium
Immuneering says it will highlight atebimetinib combination potential in pancreatic and anaplastic thyroid cancers at the 2026 EORTC-NCI-AACR Symposium. The supplied body says combination therapy with chemotherapy has shown results in Phase 2 clinical trials.
Story updates
12:37:00 PM UTC
SquawkNews
Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP, as presented in June at ASCO -- Poster spotlight session will highlight br…